Ann M. Berger,Amy Pickar Abernethy,Ashley Atkinson,Andrea M. Barsevick,William Breitbart,David Cella,Bernadine Cimprich,Charles S. Cleeland,Mario A. Eisenberger,Carmen P. Escalante,Paul B. Jacobsen,Phyllis Kaldor,Jennifer A. Ligibel,Barbara A. Murphy,Tracey L. O’Connor,William F. Pirl,Eve T. Rodler,Hope S. Rugo,James Thomas,Lynne I. Wagner
出处
期刊:Journal of The National Comprehensive Cancer Network日期:2010-08-01卷期号:8 (8): 904-931被引量:255
NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial.Participation in clinical trials is especially encouraged.